lung cancer Integration of IgA and IgG Autoantigens Improves Performance of Biomarker Panels for Early Diagnosis of Lung Cancer [Research] By feedproxy.google.com Published On :: 2020-03-01T00:05:26-08:00 Lung cancer (LC) remains the leading cause of mortality from malignant tumors worldwide. In our previous study, we surveyed both IgG and IgM-bound serological biomarkers and validated a panel of IgG-bound autoantigens for early LC diagnosis with 50% sensitivity at 90% specificity. To further improve the performance of these serological biomarkers, we surveyed HuProt arrays, comprised of 20,240 human proteins, for IgA-bound autoantigens because IgAs are a major immunoglobulin isotype in the lung. Integrating with IgG-bound autoantigens, we discovered and validated a combined biomarker panel using ELISA-format tests. Specifically, in Phase I, we obtained IgA-based autoimmune profiles of 69 early stage LC patients, 30 healthy subjects and 25 patients with lung benign lesions (LBL) on HuProt arrays and identified 28 proteins as candidate autoantigens that were significantly associated with early stage LC. In Phase II, we re-purified the autoantigens and converted them into an ELISA-format testing to profile an additional large cohort, comprised of 136 early stage LC patients, 58 healthy individuals, and 29 LBL patients. Integration of IgG autoimmune profiles allowed us to identify and validate a biomarker panel of three IgA autoantigens (i.e. BCL7A, and TRIM33 and MTERF4) and three IgG autoantigens (i.e. CTAG1A, DDX4 and MAGEC2) for diagnosis of early stage LC with 73.5% sensitivity at >85% specificity. In Phase III, the performance of this biomarker panel was confirmed with an independent cohort, comprised of 88 early stage LC patients, 18 LBL patients, and 36 healthy subjects. Finally, a blind test on 178 serum samples was conducted to confirm the performance of the biomarker panel. In summary, this study demonstrates for the first time that an integrated panel of IgA/IgG autoantigens can serve as valuable biomarkers to further improve the performance of early diagnosis of LC. Full Article
lung cancer DPH Urges Delawareans at High Risk of Lung Cancer to Get Life-Saving Screenings By news.delaware.gov Published On :: Wed, 17 Apr 2019 20:46:19 +0000 April Designated as Lung Cancer Screening Awareness Month DOVER – Dramatic “before-and-after-smoking” inflatable lungs shared center stage with Governor John Carney as he urged Delawareans at high risk of lung cancer to get life-saving screenings. Governor Carney proclaimed April as Lung Cancer Screening Awareness Month in Delaware at the Delaware Cancer Consortium’s (DCC) annual retreat […] Full Article Delaware Health and Social Services Division of Public Health News cancer prevention cancer screening DE Division of Public Health Delaware Cancer Consortium lung cancer public health
lung cancer FDA approves Eli Lilly drug for thyroid, lung cancers driven by a genetic mutation By feeds.reuters.com Published On :: Fri, 08 May 2020 17:58:16 -0400 The U.S. Food and Drug Administration on Friday approved a drug to treat lung and thyroid cancers driven by a specific genetic mutation that Eli Lilly and Co acquired with its 2019 purchase of Loxo Oncology. Full Article companyNews
lung cancer Acrylamide Doesn't Raise Lung Cancer Risk By www.medicinenet.com Published On :: Sat, 9 May 2020 00:00:00 PDT Title: Acrylamide Doesn't Raise Lung Cancer RiskCategory: Health NewsCreated: 4/29/2009 2:00:00 AMLast Editorial Review: 4/29/2009 12:00:00 AM Full Article
lung cancer Lung Cancer Surgery May Be Safest at High-Volume Hospitals, Study Finds By www.medicinenet.com Published On :: Sat, 9 May 2020 00:00:00 PDT Title: Lung Cancer Surgery May Be Safest at High-Volume Hospitals, Study FindsCategory: Health NewsCreated: 4/29/2014 12:35:00 PMLast Editorial Review: 4/30/2014 12:00:00 AM Full Article
lung cancer Drugs Show Promise for Some Advanced Lung Cancers By www.medicinenet.com Published On :: Sat, 9 May 2020 00:00:00 PDT Title: Drugs Show Promise for Some Advanced Lung CancersCategory: Health NewsCreated: 4/29/2015 12:00:00 AMLast Editorial Review: 4/30/2015 12:00:00 AM Full Article
lung cancer Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel [Articles] By dmd.aspetjournals.org Published On :: 2020-04-16T08:31:41-07:00 Paclitaxel has been considered to cause OATP1B-mediated drug-drug interactions at therapeutic doses; however, its clinical relevance has not been demonstrated. This study aimed to elucidate in vivo inhibition potency of paclitaxel against OATP1B1 and OATP1B3 using endogenous OATP1B biomarkers. Paclitaxel is an inhibitor of OATP1B1 and OATP1B3, with Ki of 0.579 ± 0.107 and 5.29 ± 3.87 μM, respectively. Preincubation potentiated its inhibitory effect on both OATP1B1 and OATP1B3, with Ki of 0.154 ± 0.031 and 0.624 ± 0.183 μM, respectively. Ten patients with non–small cell lung cancer who received 200 mg/m2 of paclitaxel by a 3-hour infusion were recruited. Plasma concentrations of 10 endogenous OATP1B biomarkers—namely, coproporphyrin I, coproporphyrin III, glycochenodeoxycholate-3-sulfate, glycochenodeoxycholate-3-glucuronide, glycodeoxycholate-3-sulfate, glycodeoxycholate-3-glucuronide, lithocholate-3-sulfate, glycolithocholate-3-sulfate, taurolithocholate-3-sulfate, and chenodeoxycholate-24-glucuronide—were determined in the patients with non–small cell lung cancer on the day before paclitaxel administration and after the end of paclitaxel infusion for 7 hours. Paclitaxel increased the area under the plasma concentration-time curve (AUC) of the endogenous biomarkers 2- to 4-fold, although a few patients did not show any increment in the AUC ratios of lithocholate-3-sulfate, glycolithocholate-3-sulfate, and taurolithocholate-3-sulfate. Therapeutic doses of paclitaxel for the treatment of non–small cell lung cancer (200 mg/m2) will cause significant OATP1B1 inhibition during and at the end of the infusion. This is the first demonstration that endogenous OATP1B biomarkers could serve as surrogate biomarkers in patients. SIGNIFICANCE STATEMENT Endogenous biomarkers can address practical and ethical issues in elucidating transporter-mediated drug-drug interaction (DDI) risks of anticancer drugs clinically. We could elucidate a significant increment of the plasma concentrations of endogenous OATP1B biomarkers after a 3-hour infusion (200 mg/m2) of paclitaxel, a time-dependent inhibitor of OATP1B, in patients with non–small cell lung cancer. The endogenous OATP1B biomarkers are useful to assess the possibility of OATP1B-mediated DDIs in patients and help in appropriately designing a dosing schedule to avoid the DDIs. Full Article
lung cancer Circular RNA hsa_circ_0014130 Inhibits Apoptosis in Non-Small Cell Lung Cancer by Sponging miR-136-5p and Upregulating BCL2 By mcr.aacrjournals.org Published On :: 2020-05-04T05:40:21-07:00 Previous studies indicated that circular RNAs (circRNA) played vital roles in the development of non–small cell lung cancer (NSCLC). Although hsa_circ_0014130 might be a potential NSCLC biomarker, its function in NSCLC remains unknown. Thus, this study aimed to investigate the role of hsa_circ_0014130 in the progression of NSCLC. The levels of hsa_circ_0014130 in NSCLC tissues and adjacent normal tissues were determined by qRT-PCR. In addition, the expressions of Bcl-2 and cleaved caspase-3 in A549 cells were detected with Western blot analysis. Meanwhile, the dual luciferase reporter system assay was used to determine the interaction of hsa_circ_0014130 and miR-136-5p or Bcl-2 and miR-136-5p in NSCLC, respectively. The level of hsa_circ_0014130 was significantly upregulated in NSCLC tissues. Downregulation of hsa_circ_0014130 markedly inhibited the proliferation and invasion of A549 cells via inducing apoptosis. In addition, downregulation of hsa_circ_0014130 inhibited the tumorigenesis of subcutaneous A549 xenograft in mice in vivo. Meanwhile, mechanistic analysis indicated that downregulation of hsa_circ_0014130 decreased the expression of miR-136-5p–targeted gene Bcl-2 via acting as a competitive "sponge" of miR-136-5p. In this study, we found that hsa_circ_0014130 was upregulated in NSCLC tissues. In addition, hsa_circ_0014130 functions as a tumor promoter in NSCLC to promote tumor growth through upregulating Bcl-2 partially via "sponging" miR-136-5p. Implications: In conclusion, hsa_circ_0014130 might function as a prognostic factor for patients with NSCLC and might be a therapeutic target for the treatment of NSCLC in future. Full Article
lung cancer A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer By openres.ersjournals.com Published On :: 2020-04-19T07:30:12-07:00 Introduction Immunotherapy has become the standard of care in advanced non-small cell lung cancer (NSCLC). We aimed to quantify the economic impact, in France, of anti-PD-1 therapy for NSCLC. Methods We used patient-level data from the national ESCAP-2011-CPHG cohort study to estimate time to treatment failure and mean cost per patient for the four label indications approved by the European Medicines Agency (EMA) for NSCLC in May 2018. To compute the budget impact, we used a microsimulation model to estimate the target populations of anti-PD-1 therapy over a 3-year period, which were combined with the annual cost of treatment. Results Overall, 11 839 patients with NSCLC were estimated to be eligible for anti-PD-1 therapy 3 years after the introduction of anti-PD-1 therapies. The mean annual cost per patient in the control group ranged from 2671 (95% CI 2149–3194) to 6412 (95% CI 5920–6903) across the four indications. The mean annual cost of treatment for the four EMA-approved indications of anti-PD-1 therapy was estimated to be 48.7 million in the control group and at 421.8 million in the immunotherapy group. The overall budget impact in 2019 is expected to amount to 373.1 million. In the sensitivity analysis, flat doses and treatment effect had the greatest influence on the budget impact. Conclusion Anti-PD-1 agents for NSCLC treatment are associated with a substantial economic burden. Full Article
lung cancer Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials By breathe.ersjournals.com Published On :: 2020-03-18T06:44:39-07:00 In low-dose computed tomography (LDCT) screening for lung cancer, all three main conditions for overdiagnosis in cancer screening are present: 1) a reservoir of slowly or nongrowing lung cancer exists; 2) LDCT is a high-resolution imaging technology with the potential to identify this reservoir; and 3) eligible screening participants have a high risk of dying from causes other than lung cancer. The degree of overdiagnosis in cancer screening is most validly estimated in high-quality randomised controlled trials (RCTs), with enough follow-up time after the end of screening to avoid lead-time bias and without contamination of the control group. Nine RCTs investigating LDCT screening were identified. Two RCTs were excluded because lung cancer incidence after the end of screening was not published. Two other RCTs using active comparators were also excluded. Therefore, five RCTs were included: two trials were at low risk of bias, two of some concern and one at high risk of bias. In a meta-analysis of the two low risk of bias RCTs including 8156 healthy current or former smokers, 49% of the screen-detected cancers were overdiagnosed. There is uncertainty about this substantial degree of overdiagnosis due to unexplained heterogeneity and low precision of the summed estimate across the two trials. Key points Nine randomised controlled trials (RCTs) on low-dose computed tomography screening were identified; five were included for meta-analysis but only two of those were at low risk of bias. In a meta-analysis of recent low risk of bias RCTs including 8156 healthy current or former smokers from developed countries, we found that 49% of the screen-detected cancers may be overdiagnosed. There is uncertainty about the degree of overdiagnosis in lung cancer screening due to unexplained heterogeneity and low precision of the point estimate. If only high-quality RCTs are included in the meta-analysis, the degree of overdiagnosis is substantial. Educational aims To appreciate that low-dose computed tomography screening for lung cancer meets all three main conditions for overdiagnosis in cancer screening: a reservoir of indolent cancers exists in the population; the screening test is able to "tap" this reservoir by detecting biologically indolent cancers as well as biologically important cancers; and the population being screened is characterised by a relatively high competing risk of death from other causes To learn about biases that might affect the estimates of overdiagnosis in randomised controlled trials in cancer screening Full Article
lung cancer Lung cancer: keep your mind open - it's not always the usual suspects! By breathe.ersjournals.com Published On :: 2020-03-18T06:44:39-07:00 Some years ago, I entered a completely unfamiliar world. This was a landscape that clinicians deal with every day but for the individual suspected of having lung cancer, it can appear hostile and scary, often misrepresented by outdated imagery, information and television portrayal. Lung cancer is not awash with celebrities admitting to having it or grand fundraising campaigns like other conditions. Despite many changes in the treatment landscape, it's still generally much more stigmatised than other cancers. Full Article
lung cancer Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial By breathe.ersjournals.com Published On :: 2020-03-18T06:44:39-07:00 Since lung cancer (LC) is still the leading cause of cancer deaths worldwide [1], early detection through screening represents an important opportunity to improve LC survival and is a priority area for cancer care. The National Lung Screening Trial (NLST) aimed to compare low-dose helical computed tomography (LDCT) with chest radiography in LC screening of current or former heavy smokers. The trial found a relative reduction in mortality from LC of 20% in those who had undergone LDCT screening. LC screening has regained prominence in the thoracic oncology literature with the completion of NELSON and other European trials, which support the role of LC screening in achieving early diagnosis and reducing mortality. A growing number of implementation pilots are providing an impetus towards organised, national programmes for LC screening, which are in need of long-term follow-up data such as those presented in this study. Full Article
lung cancer Lung cancer incidence and mortality with extended follow-up in the National LungScreening Trial By breathe.ersjournals.com Published On :: 2020-03-18T06:44:39-07:00 A 78-year-old male presented at the emergency room complaining of dry cough, fever up to 38.5 °C and malaise for 1 month. He had visited a general practitioner and received amoxicillin 500 mg three times a day for 7 days for a presumed chest infection, without improvement. He had a history of diabetes and arterial blood hypertension, for which he was receiving metformin 1000 mg twice a day and amlodipine 10 mg a day for 7 years. He reported no alcohol abuse and was an ex-smoker of 20 pack-years (quit 30 years ago). He had no recent hospitalisations or any medical interventions. Full Article
lung cancer ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer By clincancerres.aacrjournals.org Published On :: 2020-05-01T00:05:36-07:00 Purpose: Currently, an optimal therapeutic strategy comprising molecularly targeted agents for treating EGFR-mutated non–small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib is not available. Therefore, the initial therapeutic intervention is crucial for the prolonged survival of these patients. The activation of anexelekto (AXL) signaling is known to be associated with intrinsic and acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). In this study, we investigated the best therapeutic strategy to combat AXL-induced tolerance to EGFR-TKIs using the novel AXL inhibitor ONO-7475. Experimental Design: We examined the efficacy of ONO-7475 in combination with EGFR-TKIs in EGFR-mutated NSCLC cells using in vitro and in vivo experiments. We investigated the correlation between AXL expression in tumors and clinical outcomes with osimertinib for EGFR-mutated NSCLC patients with acquired resistance to initial EGFR-TKIs. Results: ONO-7475 sensitized AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs osimertinib and dacomitinib. In addition, ONO-7475 suppressed the emergence and maintenance of EGFR-TKI–tolerant cells. In the cell line–derived xenograft models of AXL-overexpressing EGFR-mutated lung cancer treated with osimertinib, initial combination therapy of ONO-7475 and osimertinib markedly regressed tumors and delayed tumor regrowth compared with osimertinib alone or the combination after acquired resistance to osimertinib. AXL expression in EGFR-TKI refractory tumors did not correlate with the sensitivity of osimertinib. Conclusions: These results demonstrate that ONO-7475 suppresses the emergence and maintenance of tolerant cells to the initial EGFR-TKIs, osimertinib or dacomitinib, in AXL-overexpressing EGFR-mutated NSCLC cells, suggesting that ONO-7475 and osimertinib is a highly potent combination for initial treatment. Full Article
lung cancer Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics By clincancerres.aacrjournals.org Published On :: 2020-05-01T00:05:36-07:00 Purpose: Using standard-of-care CT images obtained from patients with a diagnosis of non–small cell lung cancer (NSCLC), we defined radiomics signatures predicting the sensitivity of tumors to nivolumab, docetaxel, and gefitinib. Experimental Design: Data were collected prospectively and analyzed retrospectively across multicenter clinical trials [nivolumab, n = 92, CheckMate017 (NCT01642004), CheckMate063 (NCT01721759); docetaxel, n = 50, CheckMate017; gefitinib, n = 46, (NCT00588445)]. Patients were randomized to training or validation cohorts using either a 4:1 ratio (nivolumab: 72T:20V) or a 2:1 ratio (docetaxel: 32T:18V; gefitinib: 31T:15V) to ensure an adequate sample size in the validation set. Radiomics signatures were derived from quantitative analysis of early tumor changes from baseline to first on-treatment assessment. For each patient, 1,160 radiomics features were extracted from the largest measurable lung lesion. Tumors were classified as treatment sensitive or insensitive; reference standard was median progression-free survival (NCT01642004, NCT01721759) or surgery (NCT00588445). Machine learning was implemented to select up to four features to develop a radiomics signature in the training datasets and applied to each patient in the validation datasets to classify treatment sensitivity. Results: The radiomics signatures predicted treatment sensitivity in the validation dataset of each study group with AUC (95 confidence interval): nivolumab, 0.77 (0.55–1.00); docetaxel, 0.67 (0.37–0.96); and gefitinib, 0.82 (0.53–0.97). Using serial radiographic measurements, the magnitude of exponential increase in signature features deciphering tumor volume, invasion of tumor boundaries, or tumor spatial heterogeneity was associated with shorter overall survival. Conclusions: Radiomics signatures predicted tumor sensitivity to treatment in patients with NSCLC, offering an approach that could enhance clinical decision-making to continue systemic therapies and forecast overall survival. Full Article
lung cancer HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers [Research Articles] By cancerdiscovery.aacrjournals.org Published On :: 2020-05-01T00:05:26-07:00 Amplification of and oncogenic mutations in ERBB2, the gene encoding the HER2 receptor tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate that HER2 ubiquitination and internalization, rather than its overexpression, are key mechanisms underlying endocytosis and consequent efficacy of the anti-HER2 antibody–drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) in lung cancer cell lines and patient-derived xenograft models. These data translated into a 51% response rate in a clinical trial of T-DM1 in 49 patients with ERBB2-amplified or -mutant lung cancers. We show that cotreatment with irreversible pan-HER inhibitors enhances receptor ubiquitination and consequent ADC internalization and efficacy. We also demonstrate that ADC switching to T-DXd, which harbors a different cytotoxic payload, achieves durable responses in a patient with lung cancer and corresponding xenograft model developing resistance to T-DM1. Our findings may help guide future clinical trials and expand the field of ADC as cancer therapy. Significance: T-DM1 is clinically effective in lung cancers with amplification of or mutations in ERBB2. This activity is enhanced by cotreatment with irreversible pan-HER inhibitors, or ADC switching to T-DXd. These results may help address unmet needs of patients with HER2-activated tumors and no approved targeted therapy. See related commentary by Rolfo and Russo, p. 643. This article is highlighted in the In This Issue feature, p. 627 Full Article
lung cancer HER2 Mutations in Non-Small Cell Lung Cancer: A Herculean Effort to Hit the Target [In the Spotlight] By cancerdiscovery.aacrjournals.org Published On :: 2020-05-01T00:05:26-07:00 Summary: Over the last two decades HER2 aberrations have been thoroughly investigated as potential therapeutic targets in advanced non–small cell lung cancer, with relatively modest results. Two articles published in this issue of Cancer Discovery further expand the knowledge on therapeutic exploitation of HER2 in lung cancer, addressing a large unmet medical need. See related article by Li et al., p. 674. See related article by Tsurutani et al., p. 688. Full Article
lung cancer NSW Government urged to hit pause on major housing development described as 'lung cancer for Sydney' By www.abc.net.au Published On :: Thu, 31 Oct 2019 11:10:00 +1100 Court documents provide insight into the shambolic and costly planning issues being created by a major housing expansion on the southern outskirts of Sydney. Full Article ABC Radio Sydney illawarra sydney Business Economics and Finance:All:All Business Economics and Finance:Industry:All Business Economics and Finance:Industry:Building and Construction Business Economics and Finance:Regional Development:All Community and Society:All:All Government and Politics:All:All Government and Politics:Local Government:All Australia:NSW:Appin 2560 Australia:NSW:Camden 2570 Australia:NSW:Menangle 2568 Australia:NSW:Sydney South 2000 Australia:NSW:Wilton 2571 Australia:NSW:Wollongong 2500
lung cancer Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation By xconomy.com Published On :: Thu, 07 May 2020 01:46:05 +0000 As cancer research reveals the genetic basis of the disease, pharmaceutical companies are pursuing targeted therapies that address certain groups of patients. One such drug from Novartis won FDA approval Wednesday, making it the first therapy cleared by the agency to treat patients whose non-small cell lung cancer (NSCLC) carries a certain genetic mutation. The […] Full Article National National blog main American Cancer Society Biotech cancer Cancer Drugs clinical trials companion diagnostic FDA Foundation Medicine Incyte kinase inhibitor Life Sciences myelofibrosis Novartis ruxolitinib
lung cancer Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer By www.pharmafile.com Published On :: Wed, 29 Apr 2020 11:49:31 +0000 A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung cancer (NSCLC) has been stopped early after showing strong overall survival benefit, it has emerged. Full Article cancer Libtayo lung cancer Regeneron Research and Development Sanofi
lung cancer FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 By www.pharmafile.com Published On :: Thu, 07 May 2020 11:35:49 +0000 The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have a mutation that leads to MET exon 14 skipping (METex14), regardless of whether they have previously received any type of treatment. Full Article Incyte Novartis pharma Tabrecta Sales and Marketing
lung cancer Checkpoint blocker plus chemo shows impact in lung cancer By www.thepharmaletter.com Published On :: Thu, 07 May 2020 10:30:00 +0100 A multi-year collaboration between China’s Innovent Biologics and USA-based Eli Lilly is bearing fruit,… Full Article Biotechnology/China/Drug Trial/Eli Lilly & Company/Gemzar/Immuno-oncology/Innovent Biologics/Research/Tyvyt/USA
lung cancer First targeted therapy for aggressive form of lung cancer approved by FDA By www.thepharmaletter.com Published On :: Thu, 07 May 2020 11:10:00 +0100 Late Wednesday, the US Food and Drug Administration said it has granted accelerated approved for Tabrecta… Full Article Biotechnology/capmatinib/Focus On/Incyte Corp/Medical Devices and Diagnostics/Novartis/Oncology/Rare diseases/Regulation/Research/Switzerland/Tabrecta/USA
lung cancer Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival By www.news.sanofi.us Published On :: Mon, 27 Apr 2020 08:40:00 -0400 - Libtayo decreased the risk of death by 32.4% compared to chemotherapy Full Article
lung cancer Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis By feeds.nature.com Published On :: 2020-05-08 Full Article
lung cancer Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer By feeds.nature.com Published On :: 2020-05-09 Full Article
lung cancer Early assessment of <i>KRAS</i> mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer By feeds.nature.com Published On :: 2020-05-07 Full Article
lung cancer Cancer-sniffing dogs detect lung cancer with 97% accuracy By www.treehugger.com Published On :: Tue, 18 Jun 2019 08:00:00 -0400 Authors of a new study say dogs may help develop over-the-counter tests capable of life-saving early detection. Full Article Living
lung cancer Grammy Award-Winning Singer Patti LaBelle Teams Up With American Lung Association's LUNG FORCE To Educate The Public About Lung Cancer - 2nd Annual Women’s Lung Health Barometer Animated Video By feedproxy.google.com Published On :: 05 Nov 2015 10:45:00 EST 2nd Annual Women’s Lung Health Barometer Animated Video Full Article Healthcare Hospitals Medical Pharmaceuticals Music New Products Services Women-related News Broadcast Feed Announcements Survey Polls & Research Clinical Trials Medical Discoveries MultiVu Video
lung cancer Quitting Smoking can Reduce Risk of Lung Cancer By www.medindia.net Published On :: Highlights: Quitting smoking at any age significantly reduces the risk of lung cancer Healthy lung cell Full Article
lung cancer Medication to Treat Lung Cancer may Improve Outcomes of Metastatic Brain Cancer By www.medindia.net Published On :: Medication used to treat non-small cell lung cancer that has metastasized, may benefit patients with metastatic brain cancers, according to a new review and analysis led by researchers at St. Full Article
lung cancer Simple Urine Test Help Detect Lung Cancer By www.medindia.net Published On :: A simple urine test can help detect the presence of proteins associated with lung cancer, said MIT researchers. This kind of noninvasive test could reduce Full Article
lung cancer COPD Associated With Lung Cancer Risk By www.medindia.net Published On :: In people who have never smoked, COPD (chronic obstructive pulmonary disease) is associated with an increased risk of lung cancer, stated research published in the journal Thorax. Full Article
lung cancer Lung Cancer Screening Guidelines During COVID-19 By www.medindia.net Published On :: New study guides clinicians on managing lung cancer screening programs and patients with lung nodules during the COVID-19 pandemic. The findings of the Full Article
lung cancer Simple blood is saving lives by detecting lung cancer years before symptoms show By www.dailymail.co.uk Published On :: Tue, 03 Mar 2020 01:28:58 GMT Rebecca Allison, 69, and Shirley Dolan, 63, were both recipients of a revolutionary blood test - called the EarlyCDT-Lung test - that detected their lung cancer years before symptoms appeared. Full Article
lung cancer Patients with blood and lung cancers three times more at risk of dying of coronavirus By www.dailymail.co.uk Published On :: Tue, 28 Apr 2020 22:38:12 GMT A new study led by Wuhan University in China has found that people with blood and lung cancers are three times more likely to die from coronavirus compared patients with other tumors. Full Article
lung cancer HIV people who smoke more likely to die of lung cancer By www.dailymail.co.uk Published On :: Mon, 18 Sep 2017 20:05:25 GMT Researchers from Massachusetts General Hospital studied HIV patients' risk of dying from the disease or from lung cancer. They found people were 10 times more likely to die from lung cancer. Full Article
lung cancer Father-of-six, 33, marries just before dying from lung cancer By www.dailymail.co.uk Published On :: Thu, 24 Oct 2019 16:28:38 GMT Gary Smart told staff at Northampton General Hospital that he wanted to die a married man after doctors gave the father of six just days to live when they diagnosed his terminal lung cancer. Full Article
lung cancer Explained: Study claims fatality rate among lung cancer patients due to coronavirus is high By www.oneindia.com Published On :: Mon, 04 May 2020 11:23:25 +0530 New York, May 04: A new study in the United States has estimated the number of fatality rate among patients suffering from cancer patients infected with the deadly coronavirus. This study is described as the largest study has found out that Full Article
lung cancer Antitumor effects of novel nickel-hydrazone complexes in lung cancer cells By feeds.rsc.org Published On :: New J. Chem., 2020, Accepted ManuscriptDOI: 10.1039/D0NJ00921K, PaperDamir Safin, Burak AY, Onur ŞAHİN, Burcu Saygideğer Demir, Yasemin Saygideger, José Maria López-de-Luzuriaga, Ghodrat MahmoudiIn this work we have synthesized and characterized two new mononuclear nickel(II) complexes [NiLI]∙CH3CN (1∙CH3CN) and [Ni(H2LII)(NCS)2]∙0.5H2O (2∙0.5H2O), fabricated from a mixture of Ni(NO3)2 and KNCS with N',N'''-(1,2-diphenylethane-1,2-diylidene)di(picolinohydrazide) (H2LI) and...The content of this RSS Feed (c) The Royal Society of Chemistry Full Article
lung cancer Nanotechnology-based targeted drug delivery systems for lung cancer / edited by Prashant Kesharwani By library.mit.edu Published On :: Sun, 30 Jun 2019 06:40:10 EDT Barker Library - T174.7.N37347 2019 Full Article
lung cancer Onc Daily: Lung Cancer Drug Approval, Practice Struggles By www.medscape.com Published On :: Thu, 7 May 2020 15:01:54 EDT These are the most important oncology stories you need to know about today. Medscape Medical News Full Article Hematology-Oncology News
lung cancer JAMA Internal Medicine : Evaluating Shared Decision Making for Lung Cancer Screening By traffic.libsyn.com Published On :: Mon, 13 Aug 2018 15:00:00 +0000 Interview with Daniel Scott. Reuland, MD MPH, author of Evaluating Shared Decision Making for Lung Cancer Screening, and Bruno Heleno, MD, PhD, author of Estimation of Overdiagnosis of Lung Cancer in Low-Dose Computed Tomography Screening Full Article
lung cancer JAMA Oncology : Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer By traffic.libsyn.com Published On :: Thu, 21 Feb 2019 16:00:00 +0000 Interview with David A. Palma, MD, PhD, author of Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer: A Phase 2 Clinical Trial Full Article
lung cancer JAMA Oncology : Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers By traffic.libsyn.com Published On :: Thu, 27 Jun 2019 15:00:00 +0000 Interview with Melinda C. Aldrich, author of Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers Full Article
lung cancer JAMA Oncology : Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab By traffic.libsyn.com Published On :: Thu, 25 Jul 2019 15:00:00 +0000 Interview with Suzanne L. Topalian, author of Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Full Article
lung cancer JAMA Oncology : Association Between BMI and Overall Survival in Advanced Non–Small Cell Lung Cancer By traffic.libsyn.com Published On :: Thu, 26 Dec 2019 16:00:00 +0000 Interview with Ganessan Kichenadasse, MBBS, FRACP, author of Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer Full Article
lung cancer Identification of Chronic Obstructive Pulmonary Disease in Lung Cancer Screening Computed Tomographic Scans By dx.doi.org Published On :: Tue, 25 Oct 2011 21:00:00 +0000 Interview with Pim A. de Jong, MD, PhD, author of Identification of Chronic Obstructive Pulmonary Disease in Lung Cancer Screening Computed Tomographic Scans Full Article
lung cancer Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs By dx.doi.org Published On :: Tue, 20 May 2014 19:59:00 +0000 Interview with Mark G. Kris, MD, author of Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs Full Article
lung cancer The relationships among pain, dyspnea and constipation to quality of life in lung cancer patients enrolled in a hospice program By digital.lib.usf.edu Published On :: Sat, 15 Feb 2014 18:43:14 -0400 Full Article